$2.25
$0.01 (+0.45%)
$2.23Day Range$2.27
Key Statistics
Market Cap
$4.80M
Shares Outstanding
2.1M
Primary Exchange
XASE
Currency
USD
Type
ADRC
IPO Date
Sep 10, 2012
Round Lot
100
Locale
US
Trading Data
Day Open
$2.25
Day High
$2.27
Day Low
$2.23
Volume
31.0K
VWAP
$2.24
Prev Close
$2.24
Transactions
--
Acc. Volume
--
About Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Identifiers
- CIK
- 0001536196
- Composite FIGI
- BBG003CMFDM2
- Share Class FIGI
- BBG003CMFFC8
- Ticker Root
- CANF
About Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF) Stock
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF) closed the 2026-09-18 session at $2.25, up 0.45% versus the previous close (+0.01). The stock opened at $2.25 and traded between $2.23 and $2.27 during that session. Session trading volume was 31K shares. The volume-weighted average price (VWAP) is $2.24.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares has a market capitalization of $4.8 million. CANF is listed on the XASE exchange. The company employs approximately 5 people. The recorded listing date is 2012-09-10.
On this page you can find market CANF stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.